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 Cancer cells exhibit many defects in cell communication that contribute to the loss of 
tissue homeostasis (excess cell proliferation, invasion, and metastasis).  The process of cancer 
formation causes a disruption in cell homeostasis, affecting the ability to respond to extracellular 
signals, as well as triggering some intracellular events which alter gap junctional intercellular 
communication (GJIC).  Previous research has shown that the first two generations of 
substituted quinolines have anti-cancer effects on human breast cancer cells. This report 
presents the synthesis and bioactivities of the third generation of substituted quinolines.  Scrape 
load/dye transfer studies showed that 100 nM of PQ15, a third generation of substituted 
quinolones, can cause a 4.5-fold increase of gap junction activity in T47D breast cancer cells.  
Furthermore, a significant decrease of cell proliferation and viability was observed in the 
presence of 200 nM PQ15 compared to control.  The expression of α-survivin was reduced to 
<18% in the treatment of 100 nM PQ15 compared to control without treatment or solvent.  
Alpha-survivin expression is upregulated in human cancers and associated with resistance to 
chemotherapy, suggesting that α-survivin prolongs the survival of cancer cells.  Thus, it has 
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been shown that substituted quinolines stimulate gap junction activity, decrease alpha survivin 
expression, and subsequently inhibit cancer cell growth. Our findings demonstrate that PQ15 
has a promising role in exerting anti-cancer activity in human breast cancer cells. 
 
Introduction 
 The influence of hormones on the development and differentiation of the mammary 
gland has been described in numerous publications in regard to the role of estrogen in ductal 
growth, progesterone in lobulo-alveolar development, and prolactin in milk secretion [1].  
However, the mechanism by which this local control of growth and differentiation of the 
constituent epithelial cell types occur is unclear.  Some candidates are locally-acting growth 
factors, epithelial-stromal interactions, and direct cell-cell communication [2].  Direct cell-cell 
communication such as gap junctions may be modulators underlying cellular differentiation and 
also co-ordinates of cellular function in the mammary gland.   
 Numerous reports have been confirmed that gap junctions are frequently decreased or 
absent in cancer cells [3].  For instance, co-culture of tumor cells with normal cells, or with 
connexin-overexpressing cells, results in growth retardation of neoplastic component by the 
establishment of functional communication as observed with dye transfer [4].  This retardation of 
tumor growth could be prevented by co-culturing transformed cells with junctional competent 
normal cells transfected with a connexin-specific antisense reagent [5].  Thus, these results 
indicate that signals from adjacent normal cells can reverse a malignant phenotype and that 
their failure to accomplish this is due to a lack of GJIC.   
 The loss of GJIC during carcinogenesis may not result from a direct disruption of a 
specific connexin gene or mRNA levels.  The cellular oncogenes downregulate GJIC by 
phosphorylating gap junction proteins, connexin 32 (Cx32) and connexin 43 (Cx43).  In the case 
of Cx43, the phosphorylation of C-terminal serine residues results directly from protein kinase C 
(PKC) [6].    Furthermore, evidence demonstrated that PKCs inhibit gap junction channels by 
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inhibiting gap junction assembly and channel gating [7].  PKC α overexpression has been 
shown to cause tumor growth, and tumor resistance to cytotoxic chemotherapy.  We have 
shown that PKC  is highly expressed in MCF-7 breast cancer cells and stimulation of PKC  in 
these cells caused a further inhibition of gap junction activity [8].   
Several studies involving breast cancer patient tissue samples show a loss of overall 
connexin protein expression or a relocalization of the connexin to intracellular compartments [9-
11]. Multiple in vitro studies confirm the loss of connexin and/or GJIC in breast cancer cells. 
Early studies showed that connexin 26 (Cx26) and Cx43 were downregulated at the mRNA level 
in primary cells derived from human breast tumors [11] as well as in breast cancer cell lines 
[10].  Furthermore, extensive studies involving the reconstitution of connexin expression in 
GJIC-deficient breast cancer cell lines have shed some light on their role in cell growth control 
and differentiation.  Re-expression of Cx43 in MDA-MB-435 breast cancer cells resulted in 
growth suppression, a regained ability to differentiate into three-dimensional (3D) structures in 
the presence of a basement membrane and, importantly, reduction of tumor growth in mice [12]. 
Interestingly, increasing cell-cell communication in Cx43 overexpressing tumor cells 
enhances drug sensitivity [13].  Cancer cells are characterized by the lack of growth control, by 
the inability to terminally differentiate and by resistance to apoptosis.  Additionally, connexins 
have shown to have a GJIC-independent role in the regulation of apoptosis, as suggested from 
the correlation of intracellular Cx26 and Cx43 expression with the presence of the proapoptotic 
factor Bak [9].  Previous work demonstrated that first and second generations of substituted 
quinolines can activate apoptotic protein, caspase 3, in addition to upregulation gap junction 
activity in breast cancer cells [14]. This supports the idea that reversed process such as 
increase or gain of GJIC in cancer cells can drive toward apoptosis of breast cancer cells.   
Furthermore, transfection of gap junction genes, connexins, into GJIC-deficient tumor cells can 
restore GJIC, growth control and reduce tumorigenicity [15].  The modulation can either 
downregulate GJIC and lead to tumor promotion or it can upregulate GJIC and lead to 
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suppression of the initiated cells [16].  Hence, increasing gap junction activity or enhancing 
GJIC in tumor cells provides the means to enhance antineoplastic therapies.    
 Based on previous synthesis, we designed and synthesized structurally similar analogs 
with enhanced bioactivity and improved drug characteristics, affording lead compounds suitable 
for preclinical development. Structure-activity relationship (SAR) studies allowed us to optimize 
the potency of these compounds through iterative medicinal/combinatorial chemistry, molecular 
modeling and in vitro testing. Therefore, this report demonstrates that the third generation of 
subsitituted quinoline, PQ15 (Figure 1), can increase gap junction activity in T47D breast cancer 
cells and significantly cause a decrease in the expression of α-survivin. 
 
Materials and Methods 
Synthesis of PQs:  A small library of PQ1 – PQ5 was first synthesized and PQ1, containing an 
aminopropyl side chain at N1’, was found to be the most active compound in both GJIC 
enhancement and anticancer activities among PQ1 – PQ5 (PQ2 – PQ5 are inactive and the 
data were not shown).  Hence, analogs of PQ1, PQ6 – PQ11, were synthesized by varying the 
N1’ substituent and studied their anticancer activities.  Fortuitously, PQ11 containing a 
furanylmethyl moiety (maintains a similar distance as that of the aminopropyl moiety of PQ1) at 
N1’ side chain shows potent anticancer activity with an IC50 value of 15.6 nM. 
 The syntheses of PQ1 and PQ11 have been reported by us [17] and the synthesis of 
PQ15, 6-methoxy-4-methyl-8-[(4-quinolinylmethyl)amino]-5-(3-trifluoromethylphenyloxy)-
quinoline, followed a similar synthetic sequence as that of PQ11.  Hence, reductive amination 
reaction of 6-methoxy-4-methyl-8-amino-5-(3-trifluoromethylphenyloxy)quinoline and 4-
quinolinecarboxaldehyde (Plobeck et al. 2000) in methanol followed by sodium 
cyanoborohydride. 
Cell line and cell culture.  T47D human breast cancer cell line was purchased from American 
Type Culture Collection (Manassas, VA).  Cells were grown in RPMI medium supplemented 
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with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 10% antibiotic-
actinomycotic at 37◦C with  5% CO2 in 75 cm
2 flasks. 
Gap Junction Activity.  For scrape load/ dye transfer (SL/DT) assay, cells were grown to 90 % 
confluency on cover slips, dosed with 10, 100, 200, and 1000 nM of PQ15 for 3 hours.  After 
that cells were washed three times with PBS.  The 2.5 μl of 1% (w/v) Lucifer yellow and .75% 
(w/v) of Rhodamine dextran was mixed and added in the center of the coverslip.  Two cuts 
crossing each other in the center of the coverslip were made.  After five minutes, cells were 
washed three times with PBS and incubated at 37 ºC in tissue culture media for 20 minutes.  
The cells were then washed with PBS three times and fixed in 2.5% paraformaldehyde for 10 
minutes.  Cells were mounted on a slide, sealed and visualized under a fluorescence 
microscope at 4X objective. 
Western Blot Analysis.  Cells were grown in serum supplemented RPMI media until they were 
90% confluent in 75 cm2 flasks.  Cells were dosed with 0, 10, 100, and 1000 nM of PQ15 for 24 
hours.  Cells were washed three times with cold PBS and then were harvested using lysis buffer 
(20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5 % Triton X-100) with 1:1000 dilution of 
protease inhibitors (Sigma-Aldrich, Saint Louis, MO).  Cell lysate was sonicated and centrifuged 
at 13,000 rpm for 30 minutes at 4ºC.  Twenty-five μg of whole cell extract was resolved by 10% 
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane 
(Midwest Scientific, Saint Louis, MO).  Nitrocellulose membrane was blocked in 5% milk for an 
hour at room temperature and then incubated with polycolonal rabbit α-survivin, 1:500 (Santa 
Cruz Biotechnologies, Santa Cruz, California), monoclonal mouse Cx43, 1:500 (Fred 
Hutchinson, Seattle, Washington), rabbit actin, 1:1,000 (Sigma-Aldrich, Saint Louis, MO).  
Western blots were detected by enhanced chemiluminescence detection reagents (Pierce, 
Rockford, Illinois, USA).   
Trypan Blue Excision.  Cell viability was measured using the trypan blue excision method.  1 x 
104 T47D breast cancer cells  were treated with various concentrations of PQ15 for 48 hours.  A 
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cell suspension was mixed with trypan blue dye and then visually examined for viable cells by 
the Cellometer Auto T4 (Nexcelom).  The graphical presentation includes at least three 
independent samples. 
Statistical analysis:  The level of significance (see * in figure legends) was considered at p < 
0.05 using Student's t test analysis. All data are presented as mean ± S.D. of at least three 
independent experiments from different batches of cultures.  
 
Results and Discussion 
 
 Approximately one in eight women is affected by breast cancer, which is the leading 
cause of death in females between the ages of 40 and 50 years in the Western world [18]. Anti-
breast cancer agents include tamoxifen (NolvadexR; partial antiestrogens), fulvestrant 
(FaslodexR; pure antiestrogens), and Lapatinib (TykerbR), as well as of aromatase inhibitor, 
FemaraR. There are several ongoing studies including pre-clinical and clinical trials with small 
drug-like molecules. Studies on gap junction enhancers onto breast cancer are limited. The 
study goal is to synthesize small molecules that specifically activate GJIC activity and inhibit 
cancer cell growth.  Previously, a small library of novel quinolines, PQ1-PQ5, was first 
synthesized and PQ1, containing an aminopropyl side chain at N1’, was found to be the most 
active compound in both GJIC enhancement and anticancer activities (14).  Hence, analogs of 
PQ1, PQ6 – PQ11, were synthesized by varying the N1’ substituent and studied their anticancer 
activities (20).  PQ15, 6-methoxy-4-methyl-8-[(4-quinolinylmethyl)amino]-5-(3-
trifluoromethylphenyloxy)-quinoline, followed a similar synthetic sequence as that of PQ11, was 
synthesized as the third generation of this quinoline class (Figure 1).  Hence, reductive 
amination reaction of 6-methoxy-4-methyl-8-amino-5-(3-trifluoromethylphenyloxy)quinoline and 
4-quinolinecarboxaldehyde (21) in methanol followed by sodium cyanoborohydride. 
A third generation of substituted quinolines was designed and their enhancement of GJs 
activities and killing of human breast cancer cells was demonstrated.  PQ15 was tested on the 
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effect of GJIC activity in T47D breast cancer cells (Figure 2A-H).  The results demonstrated that 
100 nM of PQ15 showed a significant increase in gap junction activity compared to controls, 
without PQ15 treatment, using scrape load/dye transfer assay (Figure 2D).  However, 1000 nM 
PQ15 did not significantly increase the gap junction activity (Figure 2F).  This may due to the 
cytotoxic effect at a higher concentration.  Furthermore, the increase of gap junction activity by 
100 and 200 nM PQ15 can be inhibited by 12-O-tetradecanoylphorbol-13-acetate (TPA) (Figure 
2G-H).  Previously, TPA has been shown to activate protein kinase C (PKC) and subsequently 
phosphorylate Cx43 on serine 262 and serine 268 [19].  The distance of dye transfer from 
section cut to the farthest cells with dye was measured.  A graphical presentation of three 
experiments indicates that 100 nM PQ15 causes a 4.5-fold increase in distance of dye transfer 
compared to control (Figure 2I); however, 200 nM TPA reduces this effect of 100 nM PQ15 from 
4.5-fold to 1.3-fold relative to control of gap junction activity.  Interestingly, 200 nM TPA was not 
sufficient to reduce gap junction activity of 200 nM PQ15 with 2.4-fold increase of gap junction 
activity.   This suggests that PQ15 increases gap junction activity in part through TPA-
phosphorylating connexin 43 pathway. Comparison to previous analogs of PQ series, PQ15 is 
less potent its precursors [14, 20]. This indicates that the structure of highly quinolines in PQ15 
is affecting the function of GJIC enhancement in T47D cells. 
 The effect of PQ15-upregulated gap junction activity in T47D cell proliferation was 
examined.  T47D cells were treated with 0, 10, 100, 200 and 1000 nM PQ15 for 48 hours.  A 
graphical presentation of three experiment results is presented in Figure 3.  The results show 
that 10 nM PQ15 is not sufficient to affect cell proliferation; however, 100, 200 and 1000 nM 
PQ15 cause a significant decrease of 18%, 30%, and 32%, respectively, in cell proliferation 
compared to control or DMSO.  This suggests that 200 nM PQ15 can cause an increase in gap 
junction activity and subsequently can decrease cell proliferation of T47D cells.  Furthermore, 
cell viability of T47D cells was also performed (Figure 4).  A 100 nM or 200 nM PQ15 for 48 
hours reduces 16% of T47D cell viability and 1000 nM PQ15 has a greater effect with 36% 
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decrease in cell viability compared to control or DMSO.   This supports the previous observation 
where 1000 nM PQ15 has less gap junction activity than 100-200 nM PQ15.  The loss of cell-
cell interaction is due to cytotoxic effect of PQ15 at 1000 nM.     
Furthermore, whole cell extract of PQ15 treatment was analyzed for the changes in gap 
junctional proteins, connexins.  Cells were treated with 10, 100, and 1000 nM PQ15 for 24 
hours.  Western blot analysis was performed against Cx43 (Figure 5A).  The results show that 
PQ15 has no effect on the total Cx43 expression; however, PQ15 causes a decrease in the 
phosphorylation of Cx43.  This suggests that the increase of gap junction activity by PQ15 is 
due to the inhibition of phosphorylation of Cx43.  The result also confirms that PQ15 and TPA 
mediate gap junction activity through the phosphorylation of Cx43.    
 Alpha-survivin expression is upregulated in human cancers and associated with 
resistance to chemotherapy, suggesting that α-survivin prolongs the survival of cancer cells.  
The next step was to determine whether PQ15 affects the survival pathway of T47D cells.  Cells 
were treated with 0, 10, 100, and 1000 nM PQ15 for 24 hours (Figure 5B).  The results show 
that 100-1000 nM PQ15 can cause a significant decrease of α-survivin expression compared to 
control or DMSO.  This supports that PQ15 inhibits the expression of α-survivin, preventing cell 
survival, and subsequently decreases the cell viability of T47D cells. 
 In conclusion, the anti-cancer activity of PQ15 in T47D cells is less potent as that of PQ1 
and PQ11.  The results imply that replacement of the furan moiety of the appendage at C8-
amine decreases potency.  However, it is important to find that an addition of a quinoline 
nucleus to the aminoquinoline PQ does not impede the anticancer activity.  From an 
immunoprecipitation assay, it was found that PQ disrupts the interaction of Cx43 and Nedd4, an 
E3 ubiquitin ligase, resulting in the inhibition of phosphorylation of Cx43 by protein kinase C and 
maintaining GJIC (data not shown).  This suggests that PQ blocks the binding of Nedd 4 with 
Cx43, and the binding site appears to accommodate relatively larger groups at C8 appended 
alkylamino moiety including an extra quinoline nucleus.  The results imply that modifications of 
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the C8 appendage can be carried out for future improvement of anticancer potency as well as 
pharmacokinetics of this class of compounds. 
 
Summary 
Breast cancer cells have reduced GJIC and a high rate of cell proliferation in comparison 
to normal mammary cells.  In the current study, the rationale is to synthesis a third generation of 
gap junction enhancers and examines the anti-cancer activity. Newly synthesized quinoline, 
PQ15, specifically enhances gap junction activity through TPA-mediated gap junction pathway.  
An increase of PQ15-induced gap junction activity causes a decrease in cell proliferation and 
cell viability.  Overall, the findings provide a promising direction that third generation of 
substituted quinolines enhances gap junction activity by preventing the phosphorylation of 


































Figure 2. Gap Junction Activity of PQ15 in T47D breast cancer cells.  T47D cells were treated 
with 0, 100, 200, and 1000 nM PQ15 for 3 hours (A, D, E and F).  Cells were treated with 200 
nM TPA alone (C), 100 nM PQ15 and 200 nM TPA (G), or 200 nM PQ15 and 200 nM TPA (H) 
for 3 hours.  Controls are media alone (A) or solvent, DMSO (B).  Scrape load/dye transfer 
assay was performed as described in Materials and Methods.  Lucifer yellow was used as a gap 
junctional dye and rhodamine-dextran was used to mark the cutting site. Fluorescence green 
indicates the passages of dye from the cutting site, showing increase of GJIC.  Graphical 





Figure 3. Effect of PQ15 on Cell Proliferation.  1x104 T47D breast cancer cells were treated with 
0, 10, 100, 200, and 1000 nM of PQ15 for 48 hours.  Controls are media alone and DMSO as 
solvent.  Total number of cells was counted and expressed in percent of control.  The graphical 
presentation of three independent samples was calculated and indicated with a statistical 
significance, *p<0.05.   
 
 
Figure 4. Effect of PQ15 on Cell Viability.  1x104 T47D breast cancer cells were treated with 
various concentrations of PQ15 for 48 hours.  A cell suspension was mixed with trypan blue dye 
and then visually examined viable cells.  The graphical presentation of three independent 





Figure 5.  Effect of PQ15 on Connexin 43 and Survivin Expression. T47D cells were treated 
with 0, 10, 100 nM, and 1000 nM PQ15 for 24 hours.  Treatment with DMSO was used as 
control.  Western blot analysis was performed.  Nitrocellulose membrane was blotted with the 
active form of Cx43 (43 kDa) and α-survivin (16.5 kDa) antibodies.  Actin acts as loading 
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